Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study

AB Gottlieb; P Gisondi; J Eells; L Peterson; A Kavanaugh

AB Gottlieb

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

P Gisondi

University of Verona, Verona

J Eells

UCB Pharma, Slough

L Peterson

UCB Pharma, Raleigh, NC

A Kavanaugh

University of California, San Diego, CA

Keywords

Psoriasis, Certolizumab

Abstract

Abstract not available.

References

1. Certolizumab Pegol Prescribing Information. Available at www.fda.gov/drugs
2. Certolizumab Pegol Summary of Product Characteristics. Available at www.ema.europa.eu/ema
3. van der Heijde D. RMD Open 2018;4:e000582
4. van der Heijde D. EULAR 2018
5. Gordon K. EADV 2019;870
6. Gordon K. EADV 2019;1556
7. Gordon K. AAD 2019
8. Coates LC. Ann Rheum Dis 2010;69:48–53

Poster PDF

Published

Jan 28, 2020

How to Cite

Gottlieb, A., Gisondi, P., Eells, J., Peterson, L., & Kavanaugh, A. (2020). Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. SKIN The Journal of Cutaneous Medicine, 4(1), S2. Retrieved from https://jofskin.org/index.php/skin/article/view/801

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, F Brock, C Arendt, M Boehnlein, K Reich, Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Gordon, RB Warren, AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich, Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
A Blauvelt, AB Gottlieb, F Fierens, F Brock, S Wiegratz, H Sofen, Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, Et al., Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
A Blauvelt, C Paul, P van de Kerkhof, RB Warren, AB Gottlieb, RG Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich, Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, C Arendt, R Rolleri, Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas

1 2 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)